What are the latest treatments for age-related macular degeneration?

Introduction

Age-related macular degeneration (AMD) is a leading cause of vision loss among older adults, particularly in the developed world. It is classified into two main types: exudative (wet) and nonexudative (dry). The treatment landscape for AMD has evolved significantly, with various therapies targeting different aspects of the disease.

Key Insights

Anti-VEGF Therapy:
- Intravitreal injections of anti-VEGF drugs (e.g., ranibizumab, bevacizumab, pegaptanib) are the current standard treatment for exudative AMD, significantly improving visual outcomes but requiring frequent administration .
Combination Therapies:
- Combining anti-VEGF therapy with other treatments, such as photodynamic therapy or steroids, may reduce the frequency of injections and improve outcomes .
Gene Therapy:
- Emerging gene therapy approaches, including single intravitreal injections, aim to reduce the treatment burden and improve visual effects by targeting the underlying genetic causes of AMD.
Nanotechnology:
- Nanotherapy offers innovative drug delivery systems that enhance the efficacy and reduce the side effects of AMD treatments.
New Anti-VEGF Agents:
- Newer anti-VEGF drugs and designed ankyrin repeat proteins (DARPins) show promise in providing longer-lasting effects, potentially reducing the frequency of injections .
Radiotherapy and Transpupillary Thermotherapy:
- These modalities are still under investigation and do not yet have a clear role in AMD treatment .
Surgical Interventions:
- Experimental surgical options are available in select centers but are not widely adopted due to their experimental nature .
Dietary Supplements and Preventive Measures:
- While prevention of AMD remains elusive, dietary supplements may play a role in managing the disease. Statins and prophylactic laser photocoagulation of drusen are still experimental.

Conclusion

The treatment landscape for age-related macular degeneration is rapidly evolving. Anti-VEGF therapy remains the cornerstone of treatment for exudative AMD, but new approaches such as gene therapy, nanotechnology, and combination therapies are showing promise in reducing treatment burdens and improving outcomes. While some experimental treatments and preventive measures are still under investigation, the future of AMD treatment looks promising with ongoing research and clinical trials.

What are the latest treatments for age-related macular degeneration?

Summary

Introduction

Key Insights

Conclusion

Sources and full results

Treatment of age‐related macular degeneration

Age-related macular degeneration (AMD) treatments include argon laser photocoagulation and photodynamic therapy, with newer approaches targeting the angiogenic pathway.

Exudative versus Nonexudative Age-Related Macular Degeneration: Physiopathology and Treatment Options

Exudative age-related macular degeneration (AMD) treatments involve intravitreal injections, while no successful treatments exist for nonexudative AMD.

Nanotechnology for Age-Related Macular Degeneration

Nanotechnology and gene therapy strategies show promise in reducing treatment burden and improving visual effects for age-related macular degeneration.

CURRENT KNOWLEDGE AND TRENDS IN AGE-RELATED MACULAR DEGENERATION: Today’s and Future Treatments

Current treatments for age-related macular degeneration focus on blocking VEGF, while future treatments aim to prevent vision loss due to scarring and address the dry form of the disease.

Current advances in the treatment of neovascular age-related macular degeneration

Neovascular age-related macular degeneration treatment advances include reducing intravitreal injections and combining anti-VEGF therapies with other treatments to improve visual outcomes and reduce treatment burden.

New treatments in age‐related macular degeneration

New treatments for age-related macular degeneration include photodynamic therapy, radiotherapy, transpupillary thermotherapy, anti-angiogenic agents, and surgical intervention, aiming to destroy CNV while maintaining the foveal neurosensory retina.

Age-related macular degeneration: current treatment and future options

VEGF inhibition therapy is the best treatment for exudative age-related macular degeneration, but future research may refine optimal treatment frequency and duration.

Emerging Therapeutic Options in Age-Related Macular Degeneration

Emerging therapeutic options, such as steroids and encapsulated cell technology, may help overcome limitations of current anti-VEGF therapy and extend the duration of effects in age-related macular degeneration.

Clinical update: new treatments for age-related macular degeneration

New anti-VEGF treatments show promise in treating age-related macular degeneration, but long-term systemic safety and long-term systemic adverse effects remain unclear.

Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches

Neovascular age-related macular degeneration treatment advances have improved, but new approaches like DARPins show promise for maintaining vision and enhancing patient compliance.

Try another search